Brain-Health VC Fund Backed by Sergey Brin Shuts Down and Merges into Family Office

Nexus NeuroTech Ventures shut down its operations as of March 31, 2026, Benzinga reported. The brain-health venture capital fund is in the process of being merged into Bayshore Global Management, according to Bloomberg as cited by Benzinga. The firm held $200 million in assets and had approximately 15 companies in its portfolio.

Nexus NeuroTech Ventures was backed by Google co-founder Sergey Brin. Brin supported the fund through his nonprofit Catalyst4. A 2024 tax filing indicated that Catalyst4 held roughly a 95% stake across multiple Nexus investment vehicles.

Companies in Nexus NeuroTech Ventures' portfolio have helped more than 200,000 individuals, Jordi Parramon stated. The portfolio includes 50+ ongoing clinical studies, Parramon added. Nexus NeuroTech Ventures was founded with a commitment to supporting solutions for neurodegenerative, neuropsychiatric, and neurodevelopmental conditions, according to Parramon.

"Through a recent acquisition, Nexus NeuroTech Ventures has concluded its operations," Parramon wrote in a post on LinkedIn. In addition, the body of clinical studies arising from this portfolio — currently 50+ ongoing studies — demonstrates the strong pipeline that has been created, providing a rigorous scientific foundation that has already yielded significant breakthroughs," he stated.

Parramon wrote a post on LinkedIn about the shutdown.

Sergey Brin is the world's fourth-richest individual with a net worth of $269 billion, according to the Bloomberg Billionaires Index as cited by Benzinga. Brin has spent decades supporting brain research. 75 billion toward advancing understanding of Parkinson's disease, according to Forbes as cited by Benzinga.

Sergey Brin's contributions to Parkinson's research are driven by his own genetic risk mutation and his mother’s diagnosis, Benzinga reported. Sergey Brin has invested in studies for autism and bipolar disorder. The Google co-founder has focused his philanthropy on brain research, including Parkinson's disease as a central area.